Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642356 · ClinicalTrials.gov registry record · Phase 4
Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off
A Phase 4 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT00642356 is a Phase 4 study that was terminated before completion, run by Novartis. The registered enrollment target is 14 participants.
The verdict
NCT00642356, a Phase 4 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effects of carbidopa/levodopa/entacapone compared to the effects of immediate-release carbidopa/levodopa on non-motor symptoms of end-of-dose wearing off in persons who have Parkinson's disease.
Interventions
- DRUG Carbidopa/levodopa/entacapone
- DRUG Immediate release carbidopa/levodopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00642356
The ClinicalTrials.gov registry entry for NCT00642356 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carbidopa/levodopa/entacapone is the first listed.
NCT00642356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00642356 about?
NCT00642356 is a clinical study titled "Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off". The purpose of this study is to test the effects of carbidopa/levodopa/entacapone compared to the effects of immediate-release carbidopa/levodopa on non-motor symptoms of end-of-dose wearing off in persons who have Parkinson's disease.
What is the current status of trial NCT00642356?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2008-03. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00642356?
The interventions under investigation include: Carbidopa/levodopa/entacapone (DRUG), Immediate release carbidopa/levodopa (DRUG).
Who is sponsoring clinical trial NCT00642356?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.